India, July 27 -- Entera Bio Ltd. (ENTX), a clinical-stage biotechnology company developing oral peptide therapies, Monday announced a securities purchase agreement for an oversubscribed private placement expected to generate approximately $275 million in gross proceeds.
Under the agreement, Entera will issue 122.96 million ordinary shares and pre-funded warrants to purchase up to 11.84 million ordinary shares at a purchase price of $2.04 per share. The private placement is expected to close on or about July 28.
Entera expects to use the net proceeds, together with existing cash, to fully fund the Phase 3 registrational program of EB613, an investigational once-daily oral parathyroid hormone or PTH 1-34 tablet for Osteoporosis, through a ...